Elite Pharmaceuticals Inc (ELTP)

[Pharma Sleuth]

8-K Out
Item 1.01 Entry Into A Material Definitive Agreement.



On June 17, 2024, Elite Pharmaceuticals, Inc. (the "Company”) and Nostrum Laboratories Inc. ("Nostrum”) entered into an Asset Purchase Agreement (the "Asset Purchase Agreement”), pursuant to which Nostrum was obligated to (i) sell to the Company all of its rights in and to the approved abbreviated new drug applications (ANDAs) for generic Norco® (Hydrocodone Bitartrate and Acetaminophen tablets, USP CII), generic Percocet® (Oxycodone Hydrochloride and Acetaminophen, USP CII), and generic Dolophine® (Methadone Hydrochloride tablets), each a "Product”, and (ii) grant to the Company a royalty-free, non-exclusive perpetual license to use the manufacturing technology, proprietary information, processes, techniques, protocols, methods, know-how, and improvements necessary or used to manufacture each Product in accordance with the applicable ANDA, in exchange for $900,000 in cash (the "Transaction”). The Asset Purchase Agreement includes customary representations and warranties and various customary covenants. The closing of the Transaction occurred on June 21, 2024.

8-K out

The foregoing description of the Asset Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the actual terms of such agreement, which will be filed as an exhibit to the Company’s Form 10-K for the fiscal year ending March 31, 2024.